Report Detail

Pharma & Healthcare Global Enoxaparin API Market Research Report 2022

  • RnM4438736
  • |
  • 11 May, 2022
  • |
  • Global
  • |
  • 94 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Enoxaparin API Market Overview

    • 1.1 Product Overview and Scope of Enoxaparin API
    • 1.2 Enoxaparin API Segment by Packaging
      • 1.2.1 Global Enoxaparin API Sales Growth Rate Comparison by Packaging (2022-2028)
      • 1.2.2 Multi Vials
      • 1.2.3 Pre-Filled Syringes
      • 1.2.4 Others
    • 1.3 Enoxaparin API Segment by Application
      • 1.3.1 Global Enoxaparin API Sales Comparison by Application: (2022-2028)
      • 1.3.2 COVID-19
      • 1.3.3 Pulmonary Embolism
      • 1.3.4 Atrial Fibrillation
      • 1.3.5 Others
    • 1.4 Global Enoxaparin API Market Size Estimates and Forecasts
      • 1.4.1 Global Enoxaparin API Revenue 2017-2028
      • 1.4.2 Global Enoxaparin API Sales 2017-2028
      • 1.4.3 Enoxaparin API Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Enoxaparin API Market Competition by Manufacturers

    • 2.1 Global Enoxaparin API Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Enoxaparin API Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Enoxaparin API Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Enoxaparin API Manufacturing Sites, Area Served, Product Type
    • 2.5 Enoxaparin API Market Competitive Situation and Trends
      • 2.5.1 Enoxaparin API Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Enoxaparin API Players Market Share by Revenue
      • 2.5.3 Global Enoxaparin API Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Enoxaparin API Retrospective Market Scenario by Region

    • 3.1 Global Enoxaparin API Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Enoxaparin API Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Enoxaparin API Market Facts & Figures by Country
      • 3.3.1 North America Enoxaparin API Sales by Country
      • 3.3.2 North America Enoxaparin API Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Enoxaparin API Market Facts & Figures by Country
      • 3.4.1 Europe Enoxaparin API Sales by Country
      • 3.4.2 Europe Enoxaparin API Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Enoxaparin API Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Enoxaparin API Sales by Region
      • 3.5.2 Asia Pacific Enoxaparin API Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Enoxaparin API Market Facts & Figures by Country
      • 3.6.1 Latin America Enoxaparin API Sales by Country
      • 3.6.2 Latin America Enoxaparin API Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
    • 3.7 Middle East and Africa Enoxaparin API Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Enoxaparin API Sales by Country
      • 3.7.2 Middle East and Africa Enoxaparin API Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Enoxaparin API Historic Market Analysis by Packaging

    • 4.1 Global Enoxaparin API Sales Market Share by Packaging (2017-2022)
    • 4.2 Global Enoxaparin API Revenue Market Share by Packaging (2017-2022)
    • 4.3 Global Enoxaparin API Price by Packaging (2017-2022)

    5 Global Enoxaparin API Historic Market Analysis by Application

    • 5.1 Global Enoxaparin API Sales Market Share by Application (2017-2022)
    • 5.2 Global Enoxaparin API Revenue Market Share by Application (2017-2022)
    • 5.3 Global Enoxaparin API Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Pfizer Inc.
      • 6.1.1 Pfizer Inc. Corporation Information
      • 6.1.2 Pfizer Inc. Description and Business Overview
      • 6.1.3 Pfizer Inc. Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Pfizer Inc. Enoxaparin API Product Portfolio
      • 6.1.5 Pfizer Inc. Recent Developments/Updates
    • 6.2 Sanofi S.A.
      • 6.2.1 Sanofi S.A. Corporation Information
      • 6.2.2 Sanofi S.A. Description and Business Overview
      • 6.2.3 Sanofi S.A. Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Sanofi S.A. Enoxaparin API Product Portfolio
      • 6.2.5 Sanofi S.A. Recent Developments/Updates
    • 6.3 GlaxoSmithKline Plc
      • 6.3.1 GlaxoSmithKline Plc Corporation Information
      • 6.3.2 GlaxoSmithKline Plc Description and Business Overview
      • 6.3.3 GlaxoSmithKline Plc Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 GlaxoSmithKline Plc Enoxaparin API Product Portfolio
      • 6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
    • 6.4 Bristol Myer Squibb Company
      • 6.4.1 Bristol Myer Squibb Company Corporation Information
      • 6.4.2 Bristol Myer Squibb Company Description and Business Overview
      • 6.4.3 Bristol Myer Squibb Company Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Bristol Myer Squibb Company Enoxaparin API Product Portfolio
      • 6.4.5 Bristol Myer Squibb Company Recent Developments/Updates
    • 6.5 Bohehringer Ingelheim
      • 6.5.1 Bohehringer Ingelheim Corporation Information
      • 6.5.2 Bohehringer Ingelheim Description and Business Overview
      • 6.5.3 Bohehringer Ingelheim Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Bohehringer Ingelheim Enoxaparin API Product Portfolio
      • 6.5.5 Bohehringer Ingelheim Recent Developments/Updates
    • 6.6 Eisai Inc.
      • 6.6.1 Eisai Inc. Corporation Information
      • 6.6.2 Eisai Inc. Description and Business Overview
      • 6.6.3 Eisai Inc. Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Eisai Inc. Enoxaparin API Product Portfolio
      • 6.6.5 Eisai Inc. Recent Developments/Updates
    • 6.7 Teva Pharmaceutical Industries Ltd.
      • 6.6.1 Teva Pharmaceutical Industries Ltd. Corporation Information
      • 6.6.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
      • 6.6.3 Teva Pharmaceutical Industries Ltd. Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Teva Pharmaceutical Industries Ltd. Enoxaparin API Product Portfolio
      • 6.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
    • 6.8 Abbot India Limited, Novartis AG
      • 6.8.1 Abbot India Limited, Novartis AG Corporation Information
      • 6.8.2 Abbot India Limited, Novartis AG Description and Business Overview
      • 6.8.3 Abbot India Limited, Novartis AG Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Abbot India Limited, Novartis AG Enoxaparin API Product Portfolio
      • 6.8.5 Abbot India Limited, Novartis AG Recent Developments/Updates
    • 6.9 ChemWerth
      • 6.9.1 ChemWerth Corporation Information
      • 6.9.2 ChemWerth Description and Business Overview
      • 6.9.3 ChemWerth Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 ChemWerth Enoxaparin API Product Portfolio
      • 6.9.5 ChemWerth Recent Developments/Updates
    • 6.10 Laboratorios Farmaceuticos ROVI SA
      • 6.10.1 Laboratorios Farmaceuticos ROVI SA Corporation Information
      • 6.10.2 Laboratorios Farmaceuticos ROVI SA Description and Business Overview
      • 6.10.3 Laboratorios Farmaceuticos ROVI SA Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Laboratorios Farmaceuticos ROVI SA Enoxaparin API Product Portfolio
      • 6.10.5 Laboratorios Farmaceuticos ROVI SA Recent Developments/Updates
    • 6.11 Gland Pharma Limited
      • 6.11.1 Gland Pharma Limited Corporation Information
      • 6.11.2 Gland Pharma Limited Enoxaparin API Description and Business Overview
      • 6.11.3 Gland Pharma Limited Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Gland Pharma Limited Enoxaparin API Product Portfolio
      • 6.11.5 Gland Pharma Limited Recent Developments/Updates
    • 6.12 Hanways Chempharma Co. Ltd
      • 6.12.1 Hanways Chempharma Co. Ltd Corporation Information
      • 6.12.2 Hanways Chempharma Co. Ltd Enoxaparin API Description and Business Overview
      • 6.12.3 Hanways Chempharma Co. Ltd Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.12.4 Hanways Chempharma Co. Ltd Enoxaparin API Product Portfolio
      • 6.12.5 Hanways Chempharma Co. Ltd Recent Developments/Updates
    • 6.13 Changzhou Qianhong Biopharma
      • 6.13.1 Changzhou Qianhong Biopharma Corporation Information
      • 6.13.2 Changzhou Qianhong Biopharma Enoxaparin API Description and Business Overview
      • 6.13.3 Changzhou Qianhong Biopharma Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.13.4 Changzhou Qianhong Biopharma Enoxaparin API Product Portfolio
      • 6.13.5 Changzhou Qianhong Biopharma Recent Developments/Updates
    • 6.14 Shenzhen Hepalink Pharmaceutical Group
      • 6.14.1 Shenzhen Hepalink Pharmaceutical Group Corporation Information
      • 6.14.2 Shenzhen Hepalink Pharmaceutical Group Enoxaparin API Description and Business Overview
      • 6.14.3 Shenzhen Hepalink Pharmaceutical Group Enoxaparin API Sales, Revenue and Gross Margin (2017-2022)
      • 6.14.4 Shenzhen Hepalink Pharmaceutical Group Enoxaparin API Product Portfolio
      • 6.14.5 Shenzhen Hepalink Pharmaceutical Group Recent Developments/Updates

    7 Enoxaparin API Manufacturing Cost Analysis

    • 7.1 Enoxaparin API Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Enoxaparin API
    • 7.4 Enoxaparin API Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Enoxaparin API Distributors List
    • 8.3 Enoxaparin API Customers

    9 Enoxaparin API Market Dynamics

    • 9.1 Enoxaparin API Industry Trends
    • 9.2 Enoxaparin API Market Drivers
    • 9.3 Enoxaparin API Market Challenges
    • 9.4 Enoxaparin API Market Restraints

    10 Global Market Forecast

    • 10.1 Enoxaparin API Market Estimates and Projections by Packaging
      • 10.1.1 Global Forecasted Sales of Enoxaparin API by Packaging (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Enoxaparin API by Packaging (2023-2028)
    • 10.2 Enoxaparin API Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Enoxaparin API by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Enoxaparin API by Application (2023-2028)
    • 10.3 Enoxaparin API Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Enoxaparin API by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Enoxaparin API by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:

      Enoxaparin is made from heparin and is one type of the low molecular weight heparin (LMWH). It is used as an anticoagulant that prevents the formation of blood clots also known as ‘blood thinner’. It is used to treat various conditions including deep vein thrombosis (DVT), pulmonary embolism in the lungs, acute coronary syndrome and heart attack.
      Industry Insights
      Due to the COVID-19 pandemic, the global Enoxaparin API market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Enoxaparin API market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Enoxaparin API landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
      Multi Vials accounting for % of the Enoxaparin API global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While COVID-19 segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
      The global major manufacturers of Enoxaparin API include Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Bristol Myer Squibb Company, Bohehringer Ingelheim, Eisai Inc., Teva Pharmaceutical Industries Ltd., Abbot India Limited, Novartis AG and ChemWerth, etc. In terms of revenue, the global 3 largest players have a % market share of Enoxaparin API in 2021.
      This report focuses on Enoxaparin API volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Enoxaparin API market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
      Key Drivers & Barriers
      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
      Post-covid-19 Outlook
      The readers in the section will understand how the Enoxaparin API market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
      Segmental Outlook
      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
      Segment by Packaging
      Multi Vials
      Pre-Filled Syringes
      Others
      Segment by Application
      COVID-19
      Pulmonary Embolism
      Atrial Fibrillation
      Others
      Regional Outlook
      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Scenario
      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
      Pfizer Inc.
      Sanofi S.A.
      GlaxoSmithKline Plc
      Bristol Myer Squibb Company
      Bohehringer Ingelheim
      Eisai Inc.
      Teva Pharmaceutical Industries Ltd.
      Abbot India Limited, Novartis AG
      ChemWerth
      Laboratorios Farmaceuticos ROVI SA
      Gland Pharma Limited
      Hanways Chempharma Co. Ltd
      Changzhou Qianhong Biopharma
      Shenzhen Hepalink Pharmaceutical Group
      Frequently Asked Questions
      Which product segment grabbed the largest share in the Enoxaparin API market?
      How is the competitive scenario of the Enoxaparin API market?
      Which are the key factors aiding the Enoxaparin API market growth?
      Which are the prominent players in the Enoxaparin API market?
      Which region holds the maximum share in the Enoxaparin API market?
      What will be the CAGR of the Enoxaparin API market during the forecast period?
      Which application segment emerged as the leading segment in the Enoxaparin API market?
      What key trends are likely to emerge in the Enoxaparin API market in the coming years?
      What will be the Enoxaparin API market size by 2028?
      Which company held the largest share in the Enoxaparin API market?


      Summary:
      Get latest Market Research Reports on Enoxaparin API. Industry analysis & Market Report on Enoxaparin API is a syndicated market report, published as Global Enoxaparin API Market Research Report 2022. It is complete Research Study and Industry Analysis of Enoxaparin API market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,322.90
      4,645.80
      2,746.30
      5,492.60
      371,461.00
      742,922.00
      225,881.00
      451,762.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report